H.C. Wainwright analyst Yi Chen raised the firm’s price target on EyePoint (EYPT) to $23 from $22 and keeps a Buy rating on the shares following the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint reports Q2 EPS (85c), consensus (80c)
- EyePoint sees cash runway into 2027
- Buy Rating for EyePoint Pharmaceuticals: Duravyu’s Competitive Edge and Reliability Drive Investment Confidence
- Positive Buy Rating for EyePoint Pharmaceuticals Driven by Promising Clinical Trials and Market Valuation
- EyePoint’s wAMD study fully enrolled ahead of expectations, says RBC Capital